^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    13h
    ARTEMIS-GC3: A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer (clinicaltrials.gov)
    P2, N=460, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    Tyvyt (sintilimab) • oxaliplatin
    18h
    Biomarker Analysis of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=28, Completed, Xijing Hospital | Recruiting --> Completed | Trial completion date: Jul 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Tevimbra (tislelizumab-jsgr)
    1d
    Hampered CD8 + ILT2 + T cell activation by HLA-G suggests a new immune checkpoint in gastric adenocarcinoma. (PubMed, Gastric Cancer)
    CD8 + T cells expressing ILT2 are overrepresented in patients with gastric adenocarcinoma, independent of PD-1 expression, and appear particularly susceptible to functional suppression in the presence of HLA-G-positive tumors. These findings highlight the immunomodulatory role of HLA-G in the tumor microenvironment and support its relevance as a potential target for personalized immunotherapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • HLA-G (Major Histocompatibility Complex, Class I, G)
    |
    HLA-G positive
    1d
    Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review. (PubMed, Front Immunol)
    This study presents a case of Claudin18.2-positive advanced gastric adenocarcinoma with peritoneal metastasis treated with a multimodal regimen: HIPEC, systemic CapeOx chemotherapy, and Claudin18.2-targeted therapy (ASKB589)...At 893 days post-diagnosis, the patient remains disease-free (PFS/DFS: 893/573 days) on adjuvant capecitabine...However, the absence of cytoreductive surgery and single-case limitations necessitate validation through randomized trials. Future research should prioritize biomarker-driven HIPEC protocols (e.g., nanoparticle-enhanced Claudin18.2-targeted delivery) and dynamic monitoring of Claudin18.2 expression during therapy.
    Review • Journal
    |
    CLDN18 (Claudin 18) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    HER-2 negative • HER-2 negative + CLDN18.2 positive
    |
    capecitabine • ASKB589
    2d
    A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=31, Terminated, Shanghai Junshi Bioscience Co., Ltd. | N=198 --> 31 | Recruiting --> Terminated; The trial was stopped early on the initiative of the sponsor on the basis of a change in the research and development strategy without safety concerns
    Enrollment change • Trial termination
    |
    Loqtorzi (toripalimab-tpzi) • tifcemalimab (TAB004)
    2d
    AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2) (clinicaltrials.gov)
    P=N/A, N=6000, Not yet recruiting, Imperial College London
    New trial
    3d
    HASCHANGE02: Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach (clinicaltrials.gov)
    P2, N=30, Recruiting, Peking University Cancer Hospital & Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    3d
    LINC01614 promoted malignant progression of stomach adenocarcinoma via miR-129-2-3p. (PubMed, Cytotechnology)
    LINC01614 may represent a novel molecular target for STAD. The online version contains supplementary material available at 10.1007/s10616-025-00870-z.
    Journal
    |
    MIR129 (MicroRNA 129) • MIR129-2 (MicroRNA 129-2)
    4d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    4d
    Depletion of LINC01133 from cancer-associated fibroblasts exacerbates the progression of gastric adenocarcinoma. (PubMed, iScience)
    In vivo studies confirmed that either overexpression of LINC01133 or inhibition of miR-199a-5p suppresses gastric adenocarcinoma cell growth. In summary, LINC01133 re-activation may serve as a potential therapeutic strategy for inhibiting metastasis in gastric adenocarcinoma.
    Journal
    |
    KLF4 (Kruppel-like factor 4) • PHLPP1 (PH Domain And Leucine Rich Repeat Protein Phosphatase 1) • CDC42 (Cell Division Cycle 42) • MIR199A (MicroRNA 199a) • LINC01133 (Long Intergenic Non-Protein Coding RNA 1133) • MAP3K11 (Mitogen-Activated Protein Kinase Kinase Kinase 11)
    7d
    Circulating tumor cells as prognostic biomarkers in advanced gastric cancer treated with CDC25B phosphatase inhibitors. (PubMed, Sci Rep)
    This analysis of a phase II randomized trial included patients with gastric adenocarcinoma treated with Menadione plus XELOX or XELOX alone. PFS analysis showed a higher risk of progression in No-CTC responders, with HRs of 2.28 at 3 months and 10.5 at 15 months (p < 0.001). Patients without CTC response had worse OS and PFS in both treatment groups, suggesting that CTC response could be a valuable predictor of clinical outcomes, warranting more intensive monitoring and tailored therapies for specific subgroups.
    Clinical • Journal • Circulating tumor cells
    |
    CDC25B (Cell Division Cycle 25B) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
    |
    capecitabine • oxaliplatin
    7d
    Tislelizumab Combined With XELOX as Neoadjuvant Therapy for G/GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=28, Completed, Xijing Hospital | Recruiting --> Completed | Trial completion date: Jul 2026 --> Oct 2025
    Trial completion • Trial completion date
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin